Search peptides, terms, sources/
Research source · 2025

The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
Adults with sepsis, 22 centres in China
Sample size
1,106 randomised (552 thymosin alpha 1, 554 placebo)
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Correction status
Erratum published: BMJ 2025;389:r1098.
Date checked
14 November 2026

Limitations

All centres were in China. An erratum has been published (BMJ 2025;389:r1098).

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.